Blue Cross Blue Shield of Massachusetts not covering Alzheimer’s drug
BOSTON, Mass. (WLNE) – Blue Cross Blue Shield of Massachusetts announced Friday it will not be covering Aduhelm, a controversial new Alzheimer’s drug.
Blue Cross says while the drug shows promise, studies do not demonstrate that the benefits outweigh the risks.
The FDA approved Aduhelm in June.
The drug is priced at 56 thousand dollars a year.
Blue Cross Blue Shield has about 2.8 million members in Massachusetts.